Wrapmanager Inc Lowers stake in Vertex Pharmaceuticals Incorporated (VRTX)

Vertex Pharmaceuticals Incorporated (VRTX) : Wrapmanager Inc reduced its stake in Vertex Pharmaceuticals Incorporated by 0.49% during the most recent quarter end. The investment management company now holds a total of 7,317 shares of Vertex Pharmaceuticals Incorporated which is valued at $690,871 after selling 36 shares in Vertex Pharmaceuticals Incorporated , the firm said in a disclosure report filed with the SEC on Nov 14, 2016.Vertex Pharmaceuticals Incorporated makes up approximately 0.28% of Wrapmanager Inc’s portfolio.

Other Hedge Funds, Including , Private Advisor Group reduced its stake in VRTX by selling 659 shares or 11.18% in the most recent quarter. The Hedge Fund company now holds 5,235 shares of VRTX which is valued at $499,210. Vertex Pharmaceuticals Incorporated makes up approx 0.02% of Private Advisor Group’s portfolio.Blackrock Group Ltd boosted its stake in VRTX in the latest quarter, The investment management firm added 57,835 additional shares and now holds a total of 2,393,578 shares of Vertex Pharmaceuticals Incorporated which is valued at $199,193,561. Vertex Pharmaceuticals Incorporated makes up approx 0.10% of Blackrock Group Ltd’s portfolio.Nordea Investment Management Ab boosted its stake in VRTX in the latest quarter, The investment management firm added 264 additional shares and now holds a total of 10,211 shares of Vertex Pharmaceuticals Incorporated which is valued at $796,458.

Vertex Pharmaceuticals Incorporated closed down -1.76 points or -1.93% at $89.44 with 12,65,388 shares getting traded on Monday. Post opening the session at $90.94, the shares hit an intraday low of $89 and an intraday high of $91.48 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

On the company’s financial health, Vertex Pharmaceuticals Incorporated reported $0.16 EPS for the quarter, missing the analyst consensus estimate by $ -0.03 based on the information available during the earnings call on Oct 25, 2016. Analyst had a consensus of $0.19. The company had revenue of $413.78 million for the quarter, compared to analysts expectations of $417.80 million. The company’s revenue was up 33.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.13 EPS.

Many Wall Street Analysts have commented on Vertex Pharmaceuticals Incorporated. H.C. Wainwright Downgraded Vertex Pharmaceuticals Incorporated on Oct 24, 2016 to ” Neutral”, Price Target of the shares are set at $85.Company shares were Reiterated by Stifel on Sep 15, 2016 to “Buy”, Firm has raised the Price Target to $ 109 from a previous price target of $105 .Vertex Pharmaceuticals Incorporated was Initiated by Raymond James to “Mkt Perform” on Sep 13, 2016.

Vertex Pharmaceuticals Incorporated (Vertex) is a global biotechnology company. The Company is engaged in the business of discovering developing manufacturing and commercializing small molecule drugs. The Company uses precision medicine approaches to create transformative drugs for patients with serious diseases in specialty markets. Vertex’s business is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF). It is also engaged in other research and early-stage development programs including programs in the areas of oncology and neurology. The Company’s product candidates include KALYDECO (ivacaftor) Lumacaftor in combination with Ivacaftor VX-661 in combination with Ivacaftor VX-803 VX-970 and VX-222. The Company’s product KALYDECO is available in the market.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Vertex Pharmaceuticals Incorporated - Is it time to Sell?

Top Brokerage Firms are advising their investors on Vertex Pharmaceuticals Incorporated. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.